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Introduction 
Palliative care services are increasingly involved in the care of patients with chronic kidney disease, 
either alone or as a comorbid condition. Because renal impairment often changes the pharmacokinetic 
and/or pharmacodynamic effects of a drug, this presents a challenge for prescribers. 
This article provides guidance for prescribing non-opioid drugs commonly used for palliative care 
symptom relief in patients with end-stage kidney disease (ESKD; i.e. Chronic Kidney Disease Stage 5, 
eGFR <15mL/ min/1.73m2) whether or not they are receiving dialysis. Opioids are not included, nor 
symptom relief in the last hours—days of life, because specific guidance is available elsewhere.1—4 
Tables have been produced to highlight, when possible, the most, intermediate and least ‘renally safe’ 
drugs for chronic use. However, sometimes the cautious use of a familiar drug may be preferable to an 
unfamiliar (albeit ‘renally safer’) one. Similarly, we do not advocate the automatic switching of patients to 
a ‘renally safer’ drug when an alternative is proving satisfactory. Finally, this article aims to complement 
and not replace specialist renal unit guidance. 
Safe prescribing in ESKD 
Pharmacologically, the most important consequence of ESKD is increased toxicity as a result of 
accumulation of a renally excreted drug ± active metabolites. ESKD also has many other 
consequences which may alter the effect of a drug, whether or not accumulation occurs, e.g. an 
enhanced sedative effect of a centrally-acting drug (Box A). 
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Box A. Drug-related consequences of ESKD5 
P h a r m a c o k i n e t i c  A b s o r p t i o n  
1 gastric pH, 1 gut wall oedema —> .I. PO absorption 
Distribution 
1 oedema/ascites —> 1 volume of distribution —> .I. effect of water soluble drugs 
1 cachexia or dehydration —> .I. volume of distribution —> 1 effect of water soluble drugs 
.I. drug removal transporters in the blood-brain barrier, e.g. p-glycoprotein —> 1 CNS effects 
.I. albumin levels and binding capacity —> 1 unbound (active) fraction of highly protein-bound drugs —> 1 effect (and 
metabolism) 
.I. tissue binding —> .I. volume of distribution —> 1 effect 
Metabolism 
.I. hepatic enzyme function, particularly CYP450 —> .I. metabolism —> variable effect depending on drug, e.g. pro-drug, 
active metabolite 
Elimination 
.I. GFR and .I. tubular secretion —> .I. elimination of parent drug/active metabolite —> 1 effect, 1 risk of toxicity 
.I. drug removal transporters, e.g. p-glycoprotein —> .I. biliary and GIT elimination —> .I. elimination of parent drug/active 
metabolite —> 1 effect, 1 risk of toxicity 
Pharmacodynamic 
Uraemia can alter the clinical response to certain drugs: 
1 sensitivity to drugs acting on the CNS 
1 risk of hyperkalaemia with potassium-sparing-drugs 
1 risk of GI bleeding or oedema with NSAIDs 
.I. efficacy or 1 toxicity of drugs such as warfarin or statins (due to altered physiological or pathological processes involved 
in other conditions) 
Electrolyte imbalance can increase the risk of cardiac arrhythmia with QT prolonging drugs 
Aims and development of the tables 
The tables and accompanying text were developed for the Palliative Care Formulary (see www.palliativedrugs. 
com) to provide user-friendly summaries to guide rational and safe prescribing in patients with ESKD (± dialysis), 
by raising awareness of: 
• suitable drugs and their starting doses 
• suitable alternatives when patients experience undesirable effects 
• the potential risks of using a less renally safe drug. 
The tables cover the most common symptom relief drug classes. Because it is generally good practice to become 
experienced in using relatively few drugs well, the list is purposely limited. 
Although ESKD is defined as an eGFR <15mL/min/1.73m2, most sources of prescribing information use creat-
inine clearance to guide drug dosing, with slight variation in the values reflecting ESKD. Thus, for the prescribing 
recommendations in Tables 1-6, a creatinine clearance of <10mL/min has been adopted. 
Initially, for each drug within each class, a full data table was produced summarizing the key 
pharmacokinetic data available from several established sources (Box B); see supplementary Appendix 1 
online. In turn, the full data were used to inform Tables 1-6. Drugs were categorized as ‘generally safe’, 
‘use cautiously’ and ‘avoid if possible’ from a purely renal perspective, according to their risk of 
accumulation with chronic use in ESKD. 
The pharmacokinetic information derived from the established sources sometimes varied and was occasionally 
contradictory. Generally, information within Tables 1-6 reflects either the best evidenced and/or the majority view 
of the established sources. Where there was a lack of data, information was sought from the wider literature (Box 
B). 
In the established sources, because specific prescribing advice was also noted to vary, additional sources 
of information were consulted (Box B). The prescribing advice was summarised separately (see 
supplementary Appendix 2 online) and circulated among the contributing authors to achieve a consensus 
view which is reflected in Tables 1-6. It is important to note that the consensus view may include off-label 
use. However, it is impractical to highlight all cases of off-label use because this can vary according to 
country, brand, indication, formulation, dose, route of administration or patient population. Prescribers should 
be aware of the implications of off-label use.6 ©2018, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Box B. Sources of information used 
Established sources 
American Hospital Formulary Service Drug Information7 
Martindale: The Complete Drug Reference8 
Oxford Specialist Handbook: Kidney disease from advanced disease to bereavement9 
Package Inserts (USA) 
Renal Drug Database10 
Summary of Product Characteristics (UK) 
Additional sources 
Antidepressants11-16 
Anti-emetics17,18 
Anti-epileptics19-23 
Benzodiazepines24-26 
Miscellaneous drugs27,28 
Prescribing advice1,12,29-33 
Use of the tables 
The tables should be used in conjunction with the accompanying text which highlights any general 
considerations for that class of drug and provides a commentary to help inform choice. As far as possible, 
specific prescribing advice is given. Even when a drug appears to be ‘renally safe’, because of the other 
effects of renal impairment (Box A), smaller starting doses and a slower titration than usual is generally 
advisable, particularly in the elderly and/or frail patient. Thus, the adage ‘start low, go slow’ will generally 
apply to the use of any drug, and particularly those with CNS effects. 
In addition to the impact of ESKD and familiarity, the selection of the most appropriate symptom relief drug 
in ESKD also requires the prescriber to consider any relevant additional factors such as the presence of 
concurrent symptoms, co-morbidities (e.g. cardiovascular disease, liver impairment), other drugs (e.g. in 
relation to risk of a drug—drug interaction, QT prolongation) and patient preference. 
Drug dosing in dialysis 
For patients on dialysis, the tables provide information on whether the effect of dialysis is sufficient to require 
a change in the dosing regimen of the drug. Unless specified otherwise, the information is relevant for both 
peritoneal dialysis (PD; continuous ambulatory or automated) and thrice weekly conventional haemodialysis 
(HD). However, because information is often limited and HD regimens are variable, some renal units adjust 
drug regimens for HD patients so that administration is timed to occur after the dialysis procedure. 
Specialist advice should be sought for those patients on more frequent conventional HD, high flux dialysis 
or haemodiafiltration; drug removal is more likely and closer monitoring is required.10 
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Antidepressants (Table 1) 
Low starting doses and cautious titration are required for all antidepressants, regardless of whether they (± 
any active metabolites) are renally excreted. In ESKD there is an increased sensitivity to drugs acting on the 
CNS coupled with a risk of enhanced central depressant effects from the variable pharmacokinetic changes 
(Box A), e.g.: 
• all the featured antidepressants (apart from venlafaxine) are highly protein bound 
• all the featured antidepressants are dependent on one or more of CYP3A4, CYP2D6, CYP2C19 and 
CYP1A2 
• metabolism will be further impaired in constitutionally poor metabolizers, e.g. amitriptyline, nortriptyline 
(CYP2D6), amitriptyline, citalopram and sertraline (CYP2C19), and the risk of toxicity increased from a 
pharmacokinetic drugedrug interaction involving an inhibitor of the CYP450 enzyme(s). 
Concurrent use of other drugs with CNS depressant activity, e.g. opioids, increases the risk of toxicity. 
Because of the time taken to accumulate, undesirable effects may become apparent only after days or 
weeks of regular use for those antidepressants with long halflives, e.g. amitriptyline, citalopram, mirtazapine, 
nortriptyline and sertraline. 
Choice of antidepressant 
From a renal perspective, the first-line antidepressant of choice for the treatment of depression in ESKD is 
sertraline. Citalopram can be used cautiously, but has a risk of prolongation of the QT interval (and increased 
risk of ventricular arrhythmia), e.g. as a result of possible accumulation, electrolyte imbalance, drug-drug 
interaction or concurrent use of other QT prolonging drugs. 
If an SSRI is not suitable, some renal units favour the cautious use of mirtazapine for depression, despite 
it being extensively excreted unchanged by the kidney and known to accumulate in ESKD. 
Amitriptyline and nortriptyline may be used with caution for neuropathic pain, but starting doses in ESKD 
should be low. The presence of cardiac co-morbidity may limit their use. 
For patients on PD or HD, none of the drugs in Table 1 require any additional changes to the ESKD 
dosing regimen. 
Table 1 
Antidepressants and ESKD. Before use, see introductory and class specific text 
Antidepressanta 
Halflife in  
normal renal  
function (h) 
Active 
metabolite(s)b 
Accumulation  
in renal  
impairmentc 
Removed  
by dialysisd 
Dose and  
comment 
Generally safe      
Sertralinee 26 No No No Dose unchanged 
     PO: start with 25mg each morning Use cautiously      Amitriptylinee 9e25 Yes Possible No Lower doses may be sufficient 
     PO: start with 10mg at night 
     Not a first-line treatment for depression Citaloprame 36 Yes Possible No Dose unchanged; lower doses may be 
      PO: start with 10mg each morning; Nortriptylinee 15e39 Yes Possible No Lower doses may be sufficient 
     PO: start with 10mg at night 
     Not a first-line treatment for depression Trazodone 5e13 Yes Possible No Lower doses may be sufficient 
     PO: start with 25e50mg at night 
     Not a first-line treatment for depression Avoid if possible      Duloxetine 8e17 No Yes No If unavoidable, use lower doses 
     PO: start with 30mg at night Mirtazapinee 20e40 Yes Yes No If unavoidable 
     PO: start with 15mg at night Venlafaxine 5 (11f) Yes Yes No If unavoidable 
     PO: start with 37.5mg daily, maximum 112 5 /      24h in divided doses 
     For HD patients 
     PO: dose after HD session to minimise undesirable effects  
awhichever antidepressant is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than 
usual titration and close monitoring of the patient is required 
bof actual or potential clinical relevance in ESKD 
cof drug and/or active metabolite(s); ‘possible’ has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds 
dsufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice 
ebecause of a long half-life and time taken to reach steady state, undesirable effects with these antidepressants may only become apparent after several 
days or weeks of regular use 
factive metabolite. 
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Anti-emetics (Table 2) 
In addition to any specific advice because of reduced elimination, for any individual anti-emetic, lower starting 
doses should be used, and then cautiously titrated to response. This is because patients are at risk of an 
enhanced central depressant effect as a result of reduced hepatic clearance (reduced CYP450 activity), 
reduced protein binding (increased unbound (active) fraction), and increased CNS levels and sensitivity (Box 
A). All of the featured anti-emetics are affected by one or more of these general consequences of renal 
impairment, albeit variably, e.g. domperidone does not cross the blood-brain barrier. 
The risk of toxicity is also greater from a pharmacokinetic drugedrug interaction involving an inhibitor of the 
CYP450 enzyme. For example, CYP3A4 inhibitors will lead to reduced metabolism of domperidone. 
The risk of prolongation of the QT interval (and the consequential increased risk of ventricular arrhythmia) 
is higher with domperidone, haloperidol, levomepromazine (methotrimeprazine) and ondansetron. The risk 
may be increased as a result of, e.g. drug accumulation, drugedrug interaction, concurrent use of other drugs 
that either prolong the QT interval or cause electrolyte imbalance. 
Because of the time taken to accumulate, undesirable effects may become apparent only after days or 
weeks of regular use, for those anti-emetics with a long halflife, e.g. cyclizine, haloperidol and 
levomepromazine. Concurrent use of other drugs with CNS depressant activity, e.g. opioids, increases the 
risk of toxicity of anti-emetics with central effects. 
Choice of anti-emetic 
Generally, all the anti-emetics used commonly in palliative care can be used in ESKD. Even those listed as 
‘use cautiously’ are regularly used, in reduced doses, on renal units. Thus, choice should be primarily guided 
by the likely cause of the nausea and vomiting along with co-morbid conditions. 
For patients on PD or HD, none of the drugs in Table 2 require any additional changes to the ESKD 
dosing regimen. 
Table 2 
Anti-emetics and ESKD. Before use, see introductory and class specific text 
Anti-emeticsa 
Halflife in  
normal renal  
function (h) 
Active 
metabolite(s)b 
Accumulation  
in renal  
impairmentc 
Removed  
by dialysisd Dose and comment 
Generally safe      
Cyclizinee 20 No No No Dose unchanged; lower doses may be 
 Granisetron 4e11 No No No Dose unchanged 
Ondansetron 3e6 No No No Dose unchanged 
Prochlorperazinee 6e20 No No No Lower doses may be sufficient 
Use cautiously      Domperidonef 7e9 No Possible No PO: maximum 10mg dailyeb.d. 
Haloperidol 12e38 Yes Possible No For occasional use, dose unchanged 
     For regular use, halve the usual dose 
     Also see Antipsychotics Table Levomepromazinee 15e30 Yes Possible No PO/SC: start with 6e6.25mg at night and p.r.n. 
up to q8h; lower doses may be sufficient, e.g. 
2.5mge3mg 
Metoclopramidef 4e6 No Yes No PO/SC: start with 5mg t.d.s., maximum 10mg 
 Promethazine 
hydrochloride 
5e14 No No No PO: start with 10mg b.d., maximum 25mg t.d.s. 
 
awhichever anti-emetic is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than 
usual titration and close monitoring of the patient is required 
bof actual or potential clinical relevance in ESKD 
cof drug and/or active metabolite(s); ‘possible’ has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds 
dsufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice 
ebecause of a long half-life and time taken to reach steady state, undesirable effects with these anti-emetics may only become apparent after several 
days or weeks of regular use 
fdomperidone and metoclopramide should be used at the lowest effective dose for the shortest possible time because of concerns over prolonged QT interval or 
drug-induced movement disorders respectively. 
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Anti-epileptics (Table 3) 
In addition to any specific advice because of reduced elimination, for any anti-epileptic, lower starting 
doses should be used, and then cautiously titrated to response. This is because patients are at risk of 
an enhanced central depressant effect as a result of reduced hepatic clearance (reduced CYP450 
activity), reduced protein-binding (increased unbound (active) fraction) and increased CNS levels and 
sensitivity (Box A). All the featured anti-epileptics are affected by one or more of these general 
consequences of renal impairment, albeit variably, e.g.: 
• reduced protein-binding affects the most highly protein-bound, e.g. phenytoin and valproate (for 
monitoring purposes, or when toxicity is suspected, the free fraction plasma concentration should be 
measured) 
• all but levetiracetam, oxcarbazepine and gabapentin/pregabalin are dependent on CYP450 
• the risk of toxicity is also greater from a pharmacokinetic drug—drug interaction involving an inhibitor of 
CYP450 or other enzymes responsible for metabolism of the anti-epileptic. For example: 
➢ CYP3A4 inhibitors will lead to reduced metabolism of carbamazepine; CYP2C9 inhibitors, of phenobar-
bital and phenytoin; and CYP2C19 inhibitors, of phenytoin 
➢ valproate, by inhibiting epoxide hydrolase may reduce the metabolism of carbamazepine. 
Concurrent use of other drugs with CNS depressant activity, e.g. opioids, increases the risk of toxicity. 
Because of the time taken to accumulate, undesirable effects may become apparent only after days or 
weeks of regular use for those anti-epileptics with a long halflife, e.g. carbamazepine, clonazepam, 
phenobarbital and phenytoin. 
Choice of anti-epileptic 
From a renal perspective, the first-line anti-epileptic of choice in ESKD is valproate. Although carbamazepine 
is also ‘renally clean’, it is disadvantaged by drug—drug interactions. There does not appear to be any good 
evidence to support the commonly quoted advice to avoid modified-release formulations of anti-epileptics in 
ESKD. 
Levetiracetam is increasingly used and the availability of a parenteral formulation is an advantage. It 
is primarily renally excreted, and thus accumulates in renal impairment. However, in reduced doses, it 
is authorized for use in ESKD (± dialysis), as are gabapentin and pregabalin. Gabapentin is used for 
pruritus and restless legs syndrome associated with ESKD,34 and this may make its use for neuropathic 
pain a sensible multiple-purpose option. 
There is an increased risk of toxicity from phenytoin; further, it is disadvantaged by drug—drug 
interactions. If it cannot be avoided, monitor plasma levels corrected for hypo-albuminaemia using the 
formula modified for ESKD.35 
Phenobarbital is not generally used except in conjunction with specialist neurological advice. 
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For patients on PD or HD, specific changes to the dosing regimens are required for gabapentin, 
levetiracetam and pregabalin. The clinical effect should be monitored carefully for valproate, as the effect 
of dialysis may be variable. 
 
©2018, Elsevier. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Table 3 
Anti-epileptics and ESKD. Before use, see introductory and class specific text  
Antiepileptica 
Halflife in  
normal renal  
function (h) 
Active 
metabolite(s)b 
Accumulation  
in renal  
impairmentc 
Removed 
by dialysisd Dose and comment 
Generally safe 
Carbamazepinee 16-36 No No No Dose unchanged 
Valproate 6-20 No Possible No Dose unchanged; lower doses may be 
sufficient 
Use cautiously 
Clonazepame 20-60 Yes Possible No Lower doses may be sufficient 
PO: start with 500microgram/24h 
Also see Benzodiazepines Table 
Gabapentin 5-7 No Yes Yes For non-dialysis or PD patients 
PO: start with 100mg on alternate nights 
and titrate slowly 
For HD patients with a urine 
output >100mL/24h 
PO: start with 100mg at night; 
consider either a supplementary 
dose after each HD session or 
timing the daily dose post HD 
For anuric HD patients 
PO: start with 100mg stat and 100mg 
after every HD session; a regular 
maintenance dose is generally not 
required 
Levetiracetam 6-8 No Yes Yes For non-dialysis patients 
PO/IV: start with 250mg b.d., maximum 
dose 500mg b.d. 
If <50kg, dose on a mg/kg basis (see 
SPC) 
For PD or HD patients 
PO/IV: start with 750mg stat and give 
the maintenance dose (above) as a 
once daily dose, consider either a 
supplementary dose of 250-500mg 
after each HD session or timing the 
daily dose post HD 
Oxcarbazepine 1-3 (9f) Yes Yes Unknown PO: maximum starting dose 150mg 
b.d.,  
lower doses may be sufficient, e.g. 
75mg b.d., titrate by 75mg at weekly 
intervals 
Pregabalin 5-9 No Yes Yes For non-dialysis or PD patients 
PO: start with 25mg once daily, maximum 
dose 75mg once daily 
For HD patients 
PO: consider either a supplementary 
dose of 25-100mg after each HD 
session or timing the daily dose 
post HD 
Avoid if possible 
Phenobarbitald 75-120 No Possible No
 If unavoidable, use only under specialist 
neurological advice 
No If unavoidable, dose as in normal 
renal  
function. Monitor plasma levels adjusted for 
hypo-albuminaemia in ESKD, see text 
awhichever antiepileptic is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than 
usual titration and close monitoring of the patient is required 
bof actual or potential clinical relevance in ESKD 
cof drug and/or active metabolite(s); ‘possible’ has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds 
dsufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice 
ebecause of a long half-life and time taken to reach steady state, undesirable effects with these anti-epileptics may only become apparent after several days 
or weeks of regular use 
factive metabolite. 
 
Phenytoind 20-60 No An increase in the free 
(unbound fraction) can 
occur to a clinically 
significant degree; high 
risk of toxicity due to 
the narrow therapeutic 
range 
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Antipsychotics (Table 4) 
In addition to any specific advice because of reduced elimination, for any individual antipsychotic, lower 
starting doses should be used, and then cautiously titrated to response. This is because patients are at 
risk of an enhanced central depressant effect as a result of reduced hepatic clearance (reduced CYP450 
activity), reduced protein-binding (increased unbound (active) fraction) and increased CNS levels and 
sensitivity (Box A). All of the featured antipsychotics are affected by one or more of these general 
consequences of renal impairment, albeit variably, e.g.: 
• all the featured antipsychotics are highly protein bound 
• all the featured antipsychotics are dependent on one or more of CYP3A4, CYP2D6, and CYP1A2; the risk 
of toxicity is greater from a pharmacokinetic drug-drug interaction with inhibitors of the relevant CYP450, 
e.g. haloperidol, quetiapine, risperidone (CYP3A4), haloperidol and risperidone (CYP2D6), and olanzapine 
(CYP1A2). 
Undesirable effects may become apparent only after days or weeks of regular use for those antipsychotics 
with long halflives, e.g. haloperidol, olanzapine, risperidone. Concurrent use of other drugs with CNS 
depressant activity, e.g. opioids, increases the risk of toxicity. 
The risk of prolongation of the QT interval (and increased risk of ventricular arrhythmia) may be higher 
with haloperidol and lowest for quetiapine. The risk may be increased as a result of, e.g. drug 
accumulation, drug‒ drug interaction, concurrent use of other drugs that either prolong the QT interval 
or cause electrolyte imbalance. 
Choice of antipsychotic 
From a renal perspective, olanzapine is a good first-line choice in ESKD; it is also least dependent on CYP450 
for its metabolism. Haloperidol can also be used cautiously, halving the dose for chronic use. For the use of 
levomepromazine as an anti-emetic, see Table 2. 
For patients on PD or HD, haloperidol, olanzapine and quetiapine do not require any additional changes to 
the ESKD dosing regimen. Risperidone should be avoided due to unpredictable drug removal. 
Table 4 
Antipsychotics and ESKD. Before use, see introductory and class specific text 
Halflife in Accumulation 
normal renal Active in renal Removed 
Antipsychotica function (h) metabolite(s)b impairmentc by dialysisd Dose and comment 
Generally safe 
Olanzapinee 34 (52 elderly) No No No Lower doses may be sufficient 
PO: maximum starting dose 5mg/24h 
Use cautiously 
Haloperidole 12-8 Yes Possible No For occasional use, dose unchanged. For 
regular use, halve the usual dose 
Also see Anti-emetics Table 
Quetiapine 6-14 Yes Possible No Lower doses may be sufficient 
PO: maximum starting dose 25mg/24h 
Avoid if possible 
Risperidonee 20f Yes Yes Yes If unavoidable, use lower doses 
PO: start with 500microgram b.d. and 
titrate in steps of 500microgram b.d. 
every 3-4 days 
For PD or HD patients 
Avoid due to unpredictable drug removal 
awhichever antipsychotic is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than 
usual titration and close monitoring of the patient is required 
bof actual or potential clinical relevance in ESKD 
cof drug and/or active metabolite(s); ‘possible’ has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds 
dsufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice 
ebecause of a long half-life and time taken to reach steady state, undesirable effects with these antipsychotics may only become apparent after several 
days or weeks of regular use 
ftotal for the parent drug and active metabolite. 
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Benzodiazepines (Table 5) 
In addition to any specific advice because of reduced elimination, for any individual benzodiazepine, 
lower starting doses should be used, and then cautiously titrated to response. This is because patients 
are at risk of an enhanced central depressant effect as a result of reduced hepatic clearance (reduced 
CYP450 activity), reduced protein-binding (increased unbound (active) fraction) and increased CNS 
levels and sensitivity (Box A). All of the featured benzodiazepines are affected by one or more of these 
general consequences of renal impairment, albeit variably, e.g. lorazepam elimination is not dependent 
on CYP450. 
The risk of toxicity is also greater from a pharmacokinetic drug-drug interaction involving an inhibitor of the 
CYP450 enzyme mostly responsible for metabolism of the benzodiazepine, e.g. clonazepam and diazepam 
(CYP3A4), and diazepam (CYP2C19). 
All the featured benzodiazepines have a long halflife and thus take time to accumulate. Undesirable effects 
may become apparent only after days or weeks of regular use. Concurrent use of other drugs with CNS 
depressant activity, e.g. opioids, increases the risk of toxicity. 
Choice of benzodiazepine 
From a renal point of view, lorazepam is a good first-line choice. Clonazepam can also be used cautiously 
and is used by some renal units for restless legs syndrome associated with ESKD. Diazepam should be 
avoided if possible due to the risks of accumulation from an active metabolite with a very long half-life. 
Even so, some patients with ESKD tolerate it. 
For patients on PD or HD, none of the drugs in Table 5 require any additional changes to the ESKD 
dosing regimen. 
Table 5 
Benzodiazepines and ESKD. Before use, see introductory and class specific text 
Benzodiazepinea 
Halflife in  
normal renal  
function (h) 
Active 
metabolite(s)b 
Accumulation  
in renal  
impairmentc 
Removed  
by dialysisd Dose and comment 
Generally safe      
Lorazepame 10-20 No No No Lower doses may be sufficient 
     SL/PO: start with  Use cautiously      Clonazepame 20-60 Yes Possible No Lower doses may be sufficient 
     PO: start with 500microgram/24h 
     Also see Anti-epileptics Table Avoid if possible      
Diazepame 25-50 (#200f) Yes Yes No If unavoidable, use half the usual 
d   
awhichever benzodiazepine is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower 
than usual titration and close monitoring of the patient is required 
bof actual or potential clinical relevance in ESKD 
cof drug and/or active metabolite(s); ‘possible’ has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds 
dsufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice 
ebecause of a long half-life and time taken to reach steady state, undesirable effects with these benzodiazepines may only become apparent after 
several days or weeks of regular use 
factive metabolite. 
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Table 6 
Miscellaneous drugs and ESKD. Before use, see introductory and class specific text 
Druga 
Halflife in  
normal renal  
function (h) 
Active 
metabolite(s)b 
Accumulation  
in renal  
impairmentc 
Removed  
by dialysisd Relative safety Dose and comments 
Antidiarrhoeals       
Loperamide 9e14 No No No Use cautiously Dose unchanged; lower doses may be sufficient 
Antimuscarinics       Glycopyrronium 1e1.5 Yes Yes Unknown Use cautiously SC: Start with 200micorgram p.r.n.; lower doses may be 
       PO: dose unchanged Hyoscine butylbromide 5e10 No No No Generally safe CSCI or PO: dose unchanged 
Bisphosphonates and denosumab      Denosumab 624 No No No Generally safe Dose unchanged; see text 
Ibandronic acid 10e72 No Yes No Use cautiously For prevention of skeletal-related events in patients with 
bone metastases in breast cancer: 
      PO: 50mg once weekly 
      IVI : 2mg in 500mL 0.9% saline or 5% glucose over 1h every 3e4 weeks 
      For tumour-induced hypercalcaemia, seek specialist renal unit advice 
Pamidronate disodium 1e27 No Yes No Avoid if possible For tumour-induced hypercalcaemia, seek specialist renal 
unit advice 
Zoledronic acid 146 No Yes No Avoid if possible See text 
Corticosteroids     Generally safe See text Laxatives     Generally safe See text Non-opioids       Paracetamol 1e4 Yes Possible No Use cautiously PO: start with 500mg q6eq8h; maximum 3g/24h 
      IV: see SPC; minimum interval 6h Nefopam 4 (10e15)e Yes Possible No Use cautiously PO: maximum 30mg t.d.s. 
NSAIDS    No Avoid if possible See text Skeletal muscle relaxants       Baclofen 3e4 No Yes Yes Avoid if possible If unavoidable 
      PO: maximum 5mg once daily 
      For HD patients 
      Dose after HD session Tizanidine 3 No Yes No Use cautiously PO: start with 2mg once daily; if necessary, slowly titrate in 2mg 
steps. Only increase the frequency of administration if a single 
daily dose is inadequate  
awhichever drug is used, because ESKD can have general effects on the pharmacokinetics and/or pharmacodynamics of a drug (see text), a slower than usual titration and close monitoring of the 
patient is required 
bof actual or potential clinical relevance in ESKD 
cof drug and/or active metabolite(s); ‘possible’ has been used when definitive data are lacking, but accumulation likely on clinical or theoretical grounds 
dsufficient to require a change in dosing regimen with PD or HD; for other forms of dialysis seek specialist advice 
efor active metabolite. 
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Miscellaneous drugs (Table 6) 
The relative safety and dose adjustments for other common palliative care drugs in ESKD are shown in 
Table 6. 
Full data have not been included for corticosteroids or laxatives. Corticosteroids, e.g. dexamethasone, 
fludrocortisone, hydrocortisone, methylprednisolone, prednisolone, can be used in normal doses. Similarly, 
commonly used laxatives, e.g. bisacodyl, docusate, lactulose, macrogols (polyethylene glycols), senna, are 
also generally safe in ESKD with doses unchanged. However, because of the amount of water required for 
their administration, macrogols should be used with caution and bulking agents, e.g. ispaghula (psyllium) 
husk, avoided completely. 
Loperamide is highly protein bound, extensively metabolised by CYP3A4 and is a substrate for p-
glycoprotein. In ESKD, lower doses may be sufficient, particularly in the presence of CYP3A4 and p-
glycoprotein inhibitors, the latter potentially increasing the amount of loperamide within the CNS and the risk 
of central opioid effects. 
Hyoscine butylbromide is generally safe in ESKD, and glycopyrronium can be used cautiously. However, 
for both, there is potential for greater CNS penetration due to the changes to the blood brain barrier. 
Of the bisphosphonates, pamidronate disodium and zoledronic acid are both nephrotoxic, whereas 
the risk of renal toxicity with ibandronic acid is no greater than placebo.36 Thus, for the reduction of 
skeletal-related events in cancer, the risk-benefit balance favours the use of ibandronic acid over other 
bisphosphonates. An alternative in this setting is denosumab, which is authorized for use in renal 
impairment and does not require dose adjustment. 
The management of tumour-induced hypercalcaemia can be complex in ESKD, because of the need 
for caution with fluid administration and presence of other potentially contributing factors, e.g. tertiary 
hyperparathyroidism, use of vitamin D analogues, calcium-based phosphate binders. Thus, specialist 
renal unit advice should be sought. 
For non-opioid analgesics, a reduced dose of paracetamol (acetaminophen) or nefopam is preferable to 
NSAIDS which should be avoided due to their nephrotoxicity. However, in anuric patients on dialysis, 
NSAIDS can be used in normal doses. 
The choice of skeletal muscle relaxant in ESKD is not straightforward; for all, changes in the integrity of 
the blood brain barrier may result in increased penetration into the CNS. Baclofen and diazepam (also see 
Table 5) are best avoided because of the risks of accumulation. Even so, many renal units report that patients 
can tolerate low doses of diazepam. However, the better long-term option may be the cautious use of 
tizanidine in reduced doses. CYP1A2 inhibitors can significantly reduce the metabolism of tizanidine, and 
the concurrent use of ciprofloxacin and fluvoxamine is contra-indicated. 
For patients on PD or HD, apart from baclofen for which dosing is recommended after HD, none of the 
featured drugs requires any additional changes to the ESKD dosing regimen. 
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